Physician profile
Brandon E Bolduc
NPI 1316415672
$3,044.66
in general payments reported to CMS, 2019-2025
25 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $666 · 2022: $466 · 2023: $743 · 2024: $748 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,912.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $467.10 | 2021-2025 | Verquvo, Winrevair |
| Novartis Pharmaceuticals Corporation | $352.23 | 2021-2025 | |
| Amgen INC. | $272.37 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $265.41 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $221.98 | 2022-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $193.96 | 2021-2024 | Farxiga, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $178.23 | 2022-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $163.95 | 2021-2023 | Onpattro |
| Astellas Pharma US INC | $144.47 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $143.96 | 2021-2024 | Xarelto |
| Edwards Lifesciences Corporation | $106.13 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.05 | 2023-2025 | Jardiance |
| Amarin Pharma, INC. | $71.33 | 2021-2022 | |
| Abbott Laboratories | $66.85 | 2023-2025 | Amplatzer Amulet, Cardiomems |
| Heartflow, INC. | $57.54 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $55.92 | 2021-2023 | Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $36.39 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $29.66 | 2025 | Assure Wcd |
| Boston Scientific Corporation | $22.32 | 2025 | Watchman |
| Sanofi-Aventis U.S. LLC | $19.97 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $19.62 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.31 | 2021 | |
| Esperion Therapeutics, INC. | $15.85 | 2021 | |
| Scpharmaceuticals INC. | $15.27 | 2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $13.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Bolduc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.